# Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

> **NCT06427668** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Spinogenix** · enrollment: 24 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** SPG302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06427668
- **Lead sponsor:** Spinogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427668, "Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06427668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*